Roivant Sciences Ltd. (ROIV) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
CLARENDON HOUSE, 2 CHURCH STREET HAMILTON HM11, HM11 |
| State of Incorp. | |
| Fiscal Year End | March 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2024 MRQ | 3/31/2024 | 3/31/2023 | 3/31/2022 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 6,535,706 | 1,676,813 | 2,060,400 | |||
| Cash and cash equivalent | 6,535,706 | 1,676,813 | 2,060,400 | |||
| Short-term investments | ||||||
| Restricted cash and investments | 3,903 | |||||
| Receivables | 53,545 | 30,379 | ||||
| Inventory, net of allowances, customer advances and progress billings | 35,251 | 2,761 | ||||
| Inventory | 35,251 | 2,761 | ||||
| Other current assets | 196,122 | 121,774 | 82,220 | |||
| Other undisclosed current assets | (88,796) | (33,140) | ||||
| Total current assets: | 6,731,828 | 1,798,587 | 2,146,523 | |||
| Noncurrent Assets | ||||||
| Finance lease, right-of-use asset, after accumulated amortization | 5,885 | |||||
| Operating lease, right-of-use asset | 46,892 | 53,251 | 61,044 | |||
| Property, plant and equipment | 19,058 | 39,086 | 25,905 | |||
| Intangible assets, net (including goodwill) | 137,842 | 144,881 | ||||
| Intangible assets, net (excluding goodwill) | 137,842 | 144,881 | ||||
| Restricted cash and investments | 9,377 | 10,291 | 9,731 | |||
| Other noncurrent assets | 39,109 | 49,482 | 16,092 | |||
| Other undisclosed noncurrent assets | 238,376 | 288,141 | 325,834 | |||
| Total noncurrent assets: | 490,654 | 591,017 | 438,606 | |||
| TOTAL ASSETS: | 7,222,482 | 2,389,604 | 2,585,129 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 228,811 | 204,959 | 162,114 | |||
| Accounts payable | 53,225 | 37,830 | 34,583 | |||
| Accrued liabilities | 175,586 | 167,129 | 127,531 | |||
| Deferred revenue | 10,147 | |||||
| Debt | 12,000 | 42,810 | ||||
| Other liabilities | 16,054 | 15,076 | 708 | |||
| Other undisclosed current liabilities | 9,893 | 9,603 | 11,398 | |||
| Total current liabilities: | 266,758 | 272,448 | 184,367 | |||
| Noncurrent Liabilities | ||||||
| Long-term debt and lease obligation | 3,574 | 272,493 | ||||
| Long-term debt, excluding current maturities | 210,025 | |||||
| Finance lease, liability | 3,574 | |||||
| Liabilities, other than long-term debt | 50,867 | 70,508 | 21,923 | |||
| Deferred revenue | 13,740 | |||||
| Other liabilities | 3,602 | 17,032 | 8,183 | |||
| Operating lease, liability | 47,265 | 53,476 | 62,468 | |||
| Other undisclosed noncurrent liabilities | 456,328 | 435,487 | 44,912 | |||
| Total noncurrent liabilities: | 507,195 | 509,569 | 339,328 | |||
| Total liabilities: | 773,953 | 782,017 | 523,695 | |||
| Temporary equity, including noncontrolling interest | 22,491 | |||||
| Equity | ||||||
| Equity, attributable to parent | 5,968,581 | 1,157,766 | 1,656,944 | |||
| Additional paid in capital | 5,396,492 | 4,933,137 | 4,421,614 | |||
| Accumulated other comprehensive income (loss) | (4,083) | (2,617) | (946) | |||
| Retained earnings (accumulated deficit) | 576,172 | (3,772,754) | (2,763,724) | |||
| Equity, attributable to noncontrolling interest | 479,948 | 449,821 | 381,999 | |||
| Total equity: | 6,448,529 | 1,607,587 | 2,038,943 | |||
| TOTAL LIABILITIES AND EQUITY: | 7,222,482 | 2,389,604 | 2,585,129 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2024 TTM | 3/31/2024 | 3/31/2023 | 3/31/2022 | ||
|---|---|---|---|---|---|
| Revenues | 124,795 | 61,280 | 55,286 | ||
| Gross profit: | 124,795 | 61,280 | 55,286 | ||
| Operating expenses | (1,231,189) | (1,236,598) | (1,406,928) | ||
| Other undisclosed operating income | 5,348,410 | ||||
| Operating income (loss): | 4,242,016 | (1,175,318) | (1,351,642) | ||
| Nonoperating income (expense) | (21,290) | 24,269 | (90,726) | ||
| Investment income, nonoperating | (15,201) | 8,461 | (87,291) | ||
| Other nonoperating income (expense) | (6,089) | 15,808 | (3,435) | ||
| Interest and debt expense | (34,778) | (27,968) | (7,041) | ||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 525,662 | ||||
| Income (loss) from continuing operations before equity method investments, income taxes: | 4,185,948 | (1,179,017) | (923,747) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 67,482 | (45,817) | |||
| Income (loss) from continuing operations before income taxes: | 4,253,430 | (1,224,834) | (923,747) | ||
| Income tax expense (benefit) | (22,224) | (5,190) | (369) | ||
| Income (loss) from continuing operations: | 4,231,206 | (1,230,024) | (924,116) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (924,116) | |
| Income from discontinued operations | 114,561 | ||||
| Net income (loss): | 4,231,206 | (1,115,463) | (924,116) | ||
| Net income attributable to noncontrolling interest | 117,720 | 106,433 | 78,854 | ||
| Net income (loss) available to common stockholders, diluted: | 4,348,926 | (1,009,030) | (845,262) | ||
Comprehensive Income ($ in thousands)
| 12/31/2024 TTM | 3/31/2024 | 3/31/2023 | 3/31/2022 | ||
|---|---|---|---|---|---|
| Net income (loss): | 4,231,206 | (1,115,463) | (924,116) | ||
| Other comprehensive income (loss) | (936) | (1,490) | (2,271) | ||
| Comprehensive income (loss): | 4,230,270 | (1,116,953) | (926,387) | ||
| Comprehensive income, net of tax, attributable to noncontrolling interest | 117,190 | 106,252 | 78,734 | ||
| Comprehensive income (loss), net of tax, attributable to parent: | 4,347,460 | (1,010,701) | (847,653) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.